DAX23.238 +0,7%ESt505.271 -0,3%Top 10 Crypto12,25 -1,6%Dow41.317 +1,4%Nas17.978 +1,5%Bitcoin82.927 -0,5%Euro1,1356 +0,5%Öl60,72 -1,2%Gold3.314 +2,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 BASF BASF11 RENK RENK73 Berkshire Hathaway A0YJQ2 Novo Nordisk A3EU6F Lufthansa 823212 Allianz 840400 Mercedes-Benz Group (ex Daimler) 710000 Siemens Energy ENER6Y BP 850517 Tesla A1CX3T HENSOLDT HAG000 Amazon 906866 Shell (ex Royal Dutch Shell) A3C99G
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester -- Berkshire Hathaway mit Gewinnrückgang - Buffett will aufhören -- Shell will wohl BP übernehmen -- BYD steigert Absatz im April -- BioNTech, NVIDIA, Rheinmetall, SAP im Fokus
Top News
PayPal-Aktie leichter: Kontaktloses Bezahlen an der Ladenkasse möglich PayPal-Aktie leichter: Kontaktloses Bezahlen an der Ladenkasse möglich
Gaspreis, Goldpreis, Ölpreis & Co aktuell Gaspreis, Goldpreis, Ölpreis & Co aktuell
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Santhera Pharmaceuticals Aktie

NeuKaufenVerkaufen
15,04 EUR +0,34 EUR +2,31 %
STU
14,46 CHF -0,22 CHF -1,50 %
SWX
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.201,78 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3EJMQ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINCH1276028821

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolSPHDF

Santhera Pharmaceuticals Aktien News

DatumMeistgelesen
Dow JonesPress Release: Santhera to Discontinue Phase 3 SIDEROS Study and Development of Puldysa(R) in Duchenne Muscular Dystrophy (DMD) and Focus on Vamorolone
Dow JonesPress Release: Santhera Announces Publication of -2-
Dow JonesPress Release: Santhera Announces Publication of Long-Term Clinical Data with Vamorolone in Patients with Duchenne Muscular Dystrophy
Dow JonesPress Release: Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids
Dow JonesPress Release: Santhera Announces Full Enrollment -2-
Dow JonesPress Release: Santhera Announces Full Enrollment of ReveraGen's Pivotal VISION-DMD Study with Vamorolone in Duchenne Muscular Dystrophy
Dow JonesPress Release: Santhera Announces Financial -3-
Dow JonesPress Release: Santhera Announces Financial Results for the First Half-Year 2020 and Updates on Corporate Progress
Dow JonesPress Release: Santhera Announces Financial -3-
Dow JonesPress Release: Santhera Announces Financial -2-
Dow JonesPress Release: Santhera Announces Financial Results for the First Half-Year 2020 and Updates on Corporate Progress
Dow JonesPress Release: Santhera Exercises Option to -2-
Dow JonesPress Release: Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
Dow JonesPress Release: Santhera Completes Capital Increase for Financing Arrangements
Dow JonesPress Release: Santhera Closes First Tranche of Financing Transaction
Dow JonesPress Release: Santhera Completes Capital Increase for Financing Arrangements
Dow JonesPress Release: Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Managed by Highbridge Capital Management
Dow JonesPress Release: Santhera Announces Completion of -2-
Dow JonesPress Release: Santhera Announces Completion of ReveraGen's Long-Term Extension Study with Vamorolone in Duchenne Muscular Dystrophy
Dow JonesPress Release: Santhera Provides Update on the Ongoing Regulatory Review of Puldysa(R) (Idebenone) by the CHMP in Duchenne Muscular Dystrophy (DMD)
Dow JonesPress Release: Santhera Completes Enrollment of -2-
Dow JonesPress Release: Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa(R) (Idebenone) in Duchenne Muscular Dystrophy (DMD)
Dow JonesAktien Schweiz schließen freundlich - Roche mit Allzeithoch
Dow JonesPress Release: Santhera and Cold Spring Harbor -2-
Dow JonesPress Release: Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat (POL6014) in COVID-19-related Acute Respiratory Distress Syndrome (ARDS)
Dow JonesPress Release: Santhera Completes Capital Increase to Create Shares for IRIS
Dow JonesPress Release: Santhera Enters into Equity-linked Financing to Provide up to CHF 12 million with the Option to Increase to up to CHF 24 million
Dow JonesAktien Schweiz mit Pandemie-Ängsten sehr schwach
Dow JonesPress Release: Santhera Reports Net Revenues 2019 and Highlights Pipeline Progress
Dow JonesPress Release: Santhera Appoints New Chief Financial Officer
Dow JonesPress Release: Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophy
Dow JonesPress Release: Santhera Appoints New Chief Executive Officer
Dow JonesPress Release: Santhera to Present Long-Term Data -2-
Dow JonesPress Release: Santhera to Present Long-Term Data with Puldysa(R) (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
Dow JonesPress Release: Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis
Dow JonesPress Release: Santhera Announces Financial -2-
Dow JonesPress Release: Santhera Announces Financial Results for the First Half-Year 2019
Dow JonesPress Release: Santhera Announces Publication by -2-
Dow JonesPress Release: Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients with Duchenne Muscular D...
Dow JonesPress Release: Santhera Announces Executive Management Change
Wer­bung

Santhera Pharmaceuticals News

Santhera Pharmaceuticals News: auf dieser Seite finden Sie alle Santhera Pharmaceuticals News und Nachrichten zur Santhera Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Santhera Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Santhera Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.